| 32.42 -0.825 (-2.48%) | 11-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.05 | 1-year : | 46.77 |
| Resists | First : | 34.29 | Second : | 40.05 |
| Pivot price | 30.69  |
|||
| Supports | First : | 28.54 |
Second : | 24.98 |
| MAs | MA(5) : | 32.61 |
MA(20) : | 30.11 |
| MA(100) : | 19.48 |
MA(250) : | 0 | |
| MACD | MACD : | 2.1 |
Signal : | 2.1 |
| %K %D | K(14,3) : | 78.8 |
D(3) : | 80.1 |
| RSI | RSI(14): 66.8 |
|||
| 52-week | High : | 34.29 | Low : | 6.71 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MAZE ] has closed below upper band by 24.8%. Bollinger Bands are 15.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 33.76 - 33.92 | 33.92 - 34.06 |
| Low: | 31.94 - 32.12 | 32.12 - 32.28 |
| Close: | 32.96 - 33.25 | 33.25 - 33.5 |
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Tue, 04 Nov 2025
Maze Therapeutics to Participate in Four Upcoming Investor Conferences - The Manila Times
Tue, 04 Nov 2025
Maze Therapeutics (NASDAQ: MAZE) to participate in four conferences; webcasts for 60 days - Stock Titan
Tue, 04 Nov 2025
Maze Therapeutics to Participate in Four Upcoming Investor Conferences - Yahoo Finance
Tue, 04 Nov 2025
Can you recover from losses in Maze Therapeutics Inc. - Market Growth Review & Safe Swing Trade Setups - newser.com
Tue, 04 Nov 2025
What is the fair value of Maze Therapeutics Inc. stock now - Weekly Profit Recap & Consistent Growth Equity Picks - newser.com
Tue, 04 Nov 2025
Is Maze Therapeutics Inc. stock oversold or undervalued - 2025 Technical Patterns & Real-Time Volume Analysis Alerts - newser.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 1.621e+007 (%) |
| Held by Institutions | 2.1 (%) |
| Shares Short | 1,630 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.23e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -5 % |
| Return on Assets (ttm) | 33.2 % |
| Return on Equity (ttm) | -30.3 % |
| Qtrly Rev. Growth | 2.5e+006 % |
| Gross Profit (p.s.) | 3.82 |
| Sales Per Share | 3.82 |
| EBITDA (p.s.) | 1.21 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -105 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 8.47 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 2.31e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|